The Morristown pharmaceutical company entered into an agreement with London-based Advanz Pharma for Ocaliva, which is used to treat patients with primary biliary cholangitis, a chronic condition.

“The acquisition of BANDOL is part of our strategic global growth plan that positions Aspargo to be first to market with an innovative oral spray solution for erectile dysfunction,” said Michael Demurjian, chairman and CEO of the Englewood Cliffs pharmaceutical company.

Amazon Web Services' Open Data Sponsorship Program will provide RCSB PDB with more than 100 terabytes of space for no-cost delivery of information to millions of scientists, educators and students worldwide working in fundamental biology, biomedicine, bioenergy, and bioengineering and biotechnology.

Senior Solutions for the Jersey Shore President Beverly Zaccherio founded her company after being laid off in 2008 from her former job at a crystal manufacturer.

The Parsippanny-based pharmaceutical company said the case involved Austedo, which is the first and only FDA-approved product to treat both tardive dyskinesia in adults and chorea associated with Huntingdon’s disease.

Citius Pharmaceuticals Executive Chairman Leonard Mazur discusses the company's pipeline and the business climate for the industry in the state.

The new space at the NICHE (Nurses Improving Care for Healthsystem Elders) Exemplar hospital comes as part of a $150 million expansion — the facility's largest in more than 50 years — dubbed The Newark Strong project.

Robert Arch brings experience from a nearly 30-year career that has included positions with Elpiscience Biopharma Ltd., Novartis, Takeda, GlaxoSmithKline and Pfizer.

The approximately 400,000-square-foot manufacturing and R&D site is expected to create hundreds of jobs.

The facilities at Robert Wood Johnson University Hospital again received a “seal of approval” from the Intersocietal Accreditation Commission.

Titled Rising Through The Pandemic, the Medical Society of New Jersey's annual meeting will take place over two days in Camden.

As part of the deal, the company expects to transfer all or a portion of the remaining equity interest in Bausch + Lomb following completion of that entity's IPO.